Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness
PLOS Global Public Health · 09.08.2023 · 3 (8) · e0001328
DOI: 10.1371/journal.pgph.0001328 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 09.08.2023. Verfasst von Richmond Owusu und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of Ghana, Accra, Ghana. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Ghana introduced rotavirus vaccine (ROTARIX 1-dose presentation) into the routine national immunization program in 2012 and switched to a different product (ROTAVAC 5-dose presentation) in 2020. ROTAVAC has a lower price per dose (US$0.85 versus US$2.15 for ROTARIX) and smaller cold chain footprint but requires more doses per regimen (three versus two). This study estimates the supply chain and service delivery costs associated with each product, the costs involved in switching products, and compares the cost-effectiveness of both products over the next ten years. We estimated the supply chain and service delivery costs associated with ROTARIX and ROTAVAC (evaluating both the 5-dose and 10-dose presentations) using primary data collected from health facilities in six of the 14 regions in the country. We estimated the costs of switching from ROTARIX to ROTAVAC using information collected from key informant interviews and financial records provided by the government. All costs were reported in 2020 US$. We used the UNIVAC decision-support model to evaluate the cost-effectiveness (US$ per disability-adjusted life-year (DALY) averted from government and societal perspectives) of ROTARIX and ROTAVAC (5-dose or 10-dose presentations) compared to no vaccination, and to each other, over a ten-year period (2020 to 2029). We ran probabilistic sensitivity analyses and other threshold analyses. The supply chain and service delivery economic cost per dose was $2.40 for ROTARIX, $1.81 for ROTAVAC 5-dose, and $1.76 for ROTAVAC 10-dose. The financial and economic cost of switching from ROTARIX to ROTAVAC 5-dose was $453,070 and $883,626, respectively. Compared to no vaccination, the cost per DALY averted was $360 for ROTARIX, $298 for ROTAVAC 5-dose, and $273 for ROTAVAC 10-dose. ROTAVAC 10-dose was the most cost-effective option and would be cost-effective at willingness-to-pay thresholds exceeding 0.12 times the national GDP per capita ($2,206 in the year 2020). The switch from ROTARIX to ROTAVAC 5-dose in 2020 was cost-saving. Rotavirus vaccination is highly cost-effective in Ghana. A switch from ROTAVAC 5-dose to ROTAVAC 10-dose would be cost-saving and should be considered.
Autor:innen und Institutionen
- School of Public Health, University of Ghana, Accra, Ghana.
- Center for Vaccine Innovation and Access, PATH, Seattle, Washington, United States of America.
- Africa Centre for Disease Control and Prevention, Addis Ababa, Ethiopia.
- Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
- Center for Vaccine Innovation and Access, PATH, Accra, Ghana.
- Expanded Programme on Immunization, Ghana Health Service, Accra, Ghana.
ORCID-Profile: Mercy Mvundura, Justice Nonvignon, Frederic Debellut
Förderung
- Bill and Melinda Gates Foundation
Zitieren
APA
Owusu, R., Mvundura, M., Nonvignon, J., Armah, G., Bawa, J., Antwi-Agyei, K. O., Amponsa-Achiano, K., Dadzie, F., Bonsu, G., Clark, A., Pecenka, C., & Debellut, F. (2023). Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness. PLOS Global Public Health, 3(8), e0001328. https://doi.org/10.1371/journal.pgph.0001328
Vancouver
Owusu R, Mvundura M, Nonvignon J, Armah G, Bawa J, Antwi-Agyei KO, et al. Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness. PLOS Global Public Health. 2023;3(8):e0001328. doi:10.1371/journal.pgph.0001328
BibTeX
@article{Owusu2023,
author = {Owusu, Richmond and Mvundura, Mercy and Nonvignon, Justice and Armah, George and Bawa, John and Antwi-Agyei, Kwadwo Odei and Amponsa-Achiano, Kwame and Dadzie, Frederick and Bonsu, George and Clark, Andrew and Pecenka, Clint and Debellut, Frederic},
title = {Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness},
journal = {PLOS Global Public Health},
year = {2023},
volume = {3},
number = {8},
pages = {e0001328},
doi = {10.1371/journal.pgph.0001328}
}
EUVIMED